Across the recent three months, 4 analysts have shared their insights on Abbott Laboratories (NYSE:ABT), expressing a variety of opinions spanning from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $125.0, with a high estimate of $128.00 and a low estimate of $121.00. This current average has increased by 6.61% from the previous average price target of $117.25.

Analyzing Analyst Ratings: A Detailed Breakdown

The perception of Abbott Laboratories by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Capture valuable insights into Abbott Laboratories's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Abbott Laboratories analyst ratings.

All You Need to Know About Abbott Laboratories

Abbott Laboratories's Financial Performance

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Negative Revenue Trend: Examining Abbott Laboratories's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -2.56% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Abbott Laboratories's net margin excels beyond industry benchmarks, reaching 14.16%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Abbott Laboratories's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.85%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Abbott Laboratories's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.97%, the company showcases efficient use of assets and strong financial health.

Debt Management: Abbott Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.41.

The Basics of Analyst Ratings

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.